Newcastle disease (ND) and Avian influenza (AI) are the major problems and the most economically important viral diseases in the poultry industry; therefore, vaccination against these diseases is considered one of the most effective ways of prevention. Extensive studies have been conducted to improve the performance of vaccines, and one of the major achievements of these studies is the preparation of adjuvants as stimulants of the immune system and one of the most important compounds in killed vaccines. An immunogenicity comparison of three adjuvants including, ISA70VG, Nano-Aluminum Hydroxide (Nano-Alum), and MF59 alone or with Nano-Selenium (Nano-Se), was performed using bivalent Newcastle plus Avian Influenza (ND+AI) killed vaccine. In this study, 105 specific-pathogen-free chicks (Ross-308) were divided into 7 treatments, including T1 (control group), T2 (ISA70VG), T3 (ISA70VG plus Nano-Se), T4 (Nano-Alum Hydroxide), T5 (Nano-Alum+Nano-Se), T6 (MF59), and T7 (MF59+Nano-Se). The vaccine was injected subcutaneously on day 21 in the back of the neck area. The blood samples were taken on days 14, 21, 28, 35, 42, and 49 post-vaccination. Serums of the samples were titrated by the haemagglutination inhibition (HI) test against Newcastle and Avian influenza. Based on the results, the highest HI test titers were observed for the T2 and T3 treatments, while the T6 and T7 treatments had the lowest titers. Moreover, regardless of the type of the adjuvants, adding Nano-Se increased the antibody titer in the vaccinated groups. In conclusion, a combination of the ISA70VG adjuvant and Nano-Se induced excellent antibody titers using bivalent ND+AI killed vaccine. |
- Swayne DE, Beck JR. Heat inactivation of avian influenza and Newcastle disease viruses in egg products. Avian Pathol. 2004;33(5):512-8.
- Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med. 2003;17(3):273-81.
- Khalili I, Ghadimipour R, Sadigh Eteghad S, Fathi Najafi M, Ebrahimi MM, Godsian N, et al. Evaluation of Immune Response Against Inactivated Avian Influenza (H9N2) Vaccine, by Using Chitosan Nanoparticles. Jundishapur J Microbiol. 2015;8(12):27035.
- MJ S. OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (Mammals, Birds and Bees) Paris, France: World Organization for Animal Health; 2004 [5th ed]
- OIE. Efficacy requirement- Chapter 3.3.14. Newcastle disease (infection with Newcastle disease virus): OIE Terrestrial Manual; 2021.
- Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004;82(5):497-505.
- May JC, Progar JJ, Chin R. The aluminum content of biological products containing aluminum adjuvants: Determination by atomic absorption spectrometry. J Biol Stand. 1984;12(2):175-83.
- Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488-96.
- Banihashemi SR, Baradaran B, Tebianian M, Majidi J, Jabbari AR, Jalali S, et al. Development of Leptospira Killed Whole Culture Vaccine Using Different Adjuvants and Evaluation of Humoral Immune Response in Hamsters. J Vaccines Vaccin. 2013;4:1-5.
- Li X, Aldayel AM, Cui Z. Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release. 2014;173:148-57.
- Sun Y, Xie X, He J, Jiang J, Niu R, Bai Y, et al.
Enhancement of immune response for Newcastle disease vaccine using a combined adjuvant solution of Astragalus polysaccharides, levamisole, and selenoprotein. Turk J Vet Anim Sci. 2013;37:516-22.
- Bomford R. Aluminium Salts: Perspectives in their use as Adjuvants. In: Gregoriadis G, Allison AC, Poste G, editors. Immunological Adjuvants and Vaccines. Boston, MA: Springer US; 1989. p. 35-41.
- Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol. 1995;6:229-48.
- He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015;11(2):477-88.
- Wu CY, Chang CY, Ma HH, Wang CW, Chen YT, Hsiao PW, et al. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Vaccine. 2014;32(35):4485-94.
- Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med. 2014;6(234):234-55.
- Black S. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine. 2015;33(2):3-5.
- Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, et al. Assessment of the immunogenicity and safety of varying doses of an MF59(R)-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Vaccine. 2012;30(33):5030-7.
- Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015;314(3):237-46.
- Knuf M, Leroux-Roels G, Rumke HC, Abarca K, Rivera L, Lattanzi M, et al. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Vaccine. 2015;33(1):174-81.
- Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357(9272):1937-43.
- O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6(5):699-710.
- OIE. Manual of diagnostic tests and vaccines for terrestrial animals: mammals, birds and bees. 2012.
- Lone NA, Spackman E, Kapczynski D. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus. Vaccine. 2017;35(26):3401-8.
- PJ M, G K. Newcastle disease. In: (Editor-in-Chief) SD, editor. Diseases of poultry. 14th ed. NJ, USA: Wiley-Blackwell; 2013. p. 112-29.
- Liu CG, Liu M, Liu F, Liu DF, Zhang Y, Pan WQ, et al. Evaluation of several adjuvants in avian influenza vaccine to chickens and ducks. Virol J. 2011;8:321.
- Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015;3(2):320-43.
- Gabalov KP, Rumina MV, Tarasenko TN, Vidyagina OS, Volkov AA, Staroverov SA, et al. The adjuvant effect of selenium nanoparticles, Triton X-114 detergent micelles, and lecithin liposomes for Escherichia coli antigens. Appl Biochem Biotechnol. 2017;53(5):587-93.
- Gabalov K, Rumina M, Tarasenko T, Vidyagina O, Volkov A, Staroverov S, et al. The adjuvant effect of selenium nanoparticles, Triton X-114 detergent micelles, and lecithin liposomes for Escherichia coli antigens. Appl Biochem Microbiol. 2017;53(5):587-93.
- Brennan KM, Crowdus CA, Cantor AH, Pescatore AJ, Barger JL, Horgan K, et al. Effects of organic and inorganic dietary selenium supplementation on gene expression profiles in oviduct tissue from broiler-breeder hens. Anim Reprod Sci. 2011;125(1-4):180-8.
- Baowei W, Guoqing H, Qiaoli W, Bin Y. Effects of yeast selenium supplementation on the growth performance, meat quality, immunity, and antioxidant capacity of goose. J Anim Physiol Anim Nutr (Berl). 2011;95(4):440-8.
- Janbakhsh A, Mansouri F, Vaziri S, Sayad B, Afsharian M, Rahimi M, et al. Effect of selenium on immune response against hepatitis B vaccine with accelerated method in insulin-dependent diabetes mellitus patients. Caspian J Intern Med. 2013;4(1):603-6.
- Arthur JR, McKenzie RC, Beckett GJ. Selenium in the immune system. J Nutr. 2003;133(5 Suppl 1):1457S-9S.
|